Meta-analysis of the likelihood of FOXC1 expression in early-and late-stage tumors

Tsutomu Kume*, Tarek Shackour

*Corresponding author for this work

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Aberrations in the expression of the transcription factor forkhead box C1 (FOXC1) have been linked to a number of malignancies. Here, we characterized the relationship between FOXC1 and cancer progression by conducting a meta-analysis of studies that reported the frequency of FOXC1 expression in tumors of different stages (T1, T2, T3, T4). Materials and Method: Relevant articles were retrieved from the Medline database by searching for the terms "FOXC1" and "cancer"; then, the retrieved articles were reviewed individually, and studies that were of multivariate cohort design, evaluated FOXC1 expression via immunohistochemical staining, and assessed the relationship between FOXC1 expression and cancer T-stage were included in our meta-analysis. Results: Our search terms identified 128 studies, 5 of which met all inclusion criteria. A total of 850 tumor samples were evaluated in the 5 studies; 452 samples were from early-stage (T1-T2) tumors, and 398 were from late-stage (T3-T4) tumors. FOXC1 was expressed in 60.7% (516/850) of all samples, in 54.6% (247/452) of early-stage tumor samples, and in 67.5% (269/398) of late-stage tumor samples. When calculated relative to early-stage samples, the pooled risk for FOXC1 expression in late-stage samples was 1.238 (95% CI = 1.061-1.444, p = 0.007). Conclusions: The results from our meta-analysis of 5 studies indicate that FOXC1 is 23.8% more likely to be expressed in late-stage tumors than in early-stage tumors.

Original languageEnglish (US)
Pages (from-to)36625-36630
Number of pages6
JournalOncotarget
Volume9
Issue number93
StatePublished - Nov 1 2018

Fingerprint

Meta-Analysis
Neoplasms
Forkhead Transcription Factors
Databases
Staining and Labeling

Keywords

  • Cancer
  • FOXC1
  • T-Stage

ASJC Scopus subject areas

  • Oncology

Cite this

@article{76fb1e4764054fdd8200b7708bd1f8aa,
title = "Meta-analysis of the likelihood of FOXC1 expression in early-and late-stage tumors",
abstract = "Background: Aberrations in the expression of the transcription factor forkhead box C1 (FOXC1) have been linked to a number of malignancies. Here, we characterized the relationship between FOXC1 and cancer progression by conducting a meta-analysis of studies that reported the frequency of FOXC1 expression in tumors of different stages (T1, T2, T3, T4). Materials and Method: Relevant articles were retrieved from the Medline database by searching for the terms {"}FOXC1{"} and {"}cancer{"}; then, the retrieved articles were reviewed individually, and studies that were of multivariate cohort design, evaluated FOXC1 expression via immunohistochemical staining, and assessed the relationship between FOXC1 expression and cancer T-stage were included in our meta-analysis. Results: Our search terms identified 128 studies, 5 of which met all inclusion criteria. A total of 850 tumor samples were evaluated in the 5 studies; 452 samples were from early-stage (T1-T2) tumors, and 398 were from late-stage (T3-T4) tumors. FOXC1 was expressed in 60.7{\%} (516/850) of all samples, in 54.6{\%} (247/452) of early-stage tumor samples, and in 67.5{\%} (269/398) of late-stage tumor samples. When calculated relative to early-stage samples, the pooled risk for FOXC1 expression in late-stage samples was 1.238 (95{\%} CI = 1.061-1.444, p = 0.007). Conclusions: The results from our meta-analysis of 5 studies indicate that FOXC1 is 23.8{\%} more likely to be expressed in late-stage tumors than in early-stage tumors.",
keywords = "Cancer, FOXC1, T-Stage",
author = "Tsutomu Kume and Tarek Shackour",
year = "2018",
month = "11",
day = "1",
language = "English (US)",
volume = "9",
pages = "36625--36630",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "93",

}

Meta-analysis of the likelihood of FOXC1 expression in early-and late-stage tumors. / Kume, Tsutomu; Shackour, Tarek.

In: Oncotarget, Vol. 9, No. 93, 01.11.2018, p. 36625-36630.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Meta-analysis of the likelihood of FOXC1 expression in early-and late-stage tumors

AU - Kume, Tsutomu

AU - Shackour, Tarek

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Background: Aberrations in the expression of the transcription factor forkhead box C1 (FOXC1) have been linked to a number of malignancies. Here, we characterized the relationship between FOXC1 and cancer progression by conducting a meta-analysis of studies that reported the frequency of FOXC1 expression in tumors of different stages (T1, T2, T3, T4). Materials and Method: Relevant articles were retrieved from the Medline database by searching for the terms "FOXC1" and "cancer"; then, the retrieved articles were reviewed individually, and studies that were of multivariate cohort design, evaluated FOXC1 expression via immunohistochemical staining, and assessed the relationship between FOXC1 expression and cancer T-stage were included in our meta-analysis. Results: Our search terms identified 128 studies, 5 of which met all inclusion criteria. A total of 850 tumor samples were evaluated in the 5 studies; 452 samples were from early-stage (T1-T2) tumors, and 398 were from late-stage (T3-T4) tumors. FOXC1 was expressed in 60.7% (516/850) of all samples, in 54.6% (247/452) of early-stage tumor samples, and in 67.5% (269/398) of late-stage tumor samples. When calculated relative to early-stage samples, the pooled risk for FOXC1 expression in late-stage samples was 1.238 (95% CI = 1.061-1.444, p = 0.007). Conclusions: The results from our meta-analysis of 5 studies indicate that FOXC1 is 23.8% more likely to be expressed in late-stage tumors than in early-stage tumors.

AB - Background: Aberrations in the expression of the transcription factor forkhead box C1 (FOXC1) have been linked to a number of malignancies. Here, we characterized the relationship between FOXC1 and cancer progression by conducting a meta-analysis of studies that reported the frequency of FOXC1 expression in tumors of different stages (T1, T2, T3, T4). Materials and Method: Relevant articles were retrieved from the Medline database by searching for the terms "FOXC1" and "cancer"; then, the retrieved articles were reviewed individually, and studies that were of multivariate cohort design, evaluated FOXC1 expression via immunohistochemical staining, and assessed the relationship between FOXC1 expression and cancer T-stage were included in our meta-analysis. Results: Our search terms identified 128 studies, 5 of which met all inclusion criteria. A total of 850 tumor samples were evaluated in the 5 studies; 452 samples were from early-stage (T1-T2) tumors, and 398 were from late-stage (T3-T4) tumors. FOXC1 was expressed in 60.7% (516/850) of all samples, in 54.6% (247/452) of early-stage tumor samples, and in 67.5% (269/398) of late-stage tumor samples. When calculated relative to early-stage samples, the pooled risk for FOXC1 expression in late-stage samples was 1.238 (95% CI = 1.061-1.444, p = 0.007). Conclusions: The results from our meta-analysis of 5 studies indicate that FOXC1 is 23.8% more likely to be expressed in late-stage tumors than in early-stage tumors.

KW - Cancer

KW - FOXC1

KW - T-Stage

UR - http://www.scopus.com/inward/record.url?scp=85063339849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063339849&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 36625

EP - 36630

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 93

ER -